Abstract
Introduction:Oxidative stress is involved in pathogenesis of Sarcoidosis. Sestrins are proteins with antioxidative capacity that accumulate in cells exposed to oxidative stress. The aim of our study was to test whether serum sestrin 2 (Ses2) levels in patients with sarcoidosis are related to disease extent, to the involvement of specific organs and to treatment with corticosteroids
Methods:Serum samples were collected from consecutive patients with sarcoidosis. Patients underwent pulmonary function tests, chest X-ray, HRCT and Positron Emission Tomography (PET). Patients with involvement of 3 or more organs were considered to have extended disease. Serum Ses2 levels were measured with ELISA
Results:35 patients (22 female) (mean age 54.0±14.4 years) were included in the study. Serum Se2 levels were higher in patients with limited disease compared to patients with extended disease [median(IQR) 3.19(1.61, 7.72) vs 0.89(0.68, 2.66)ng/mL, respectively p=0.009. Steroid naive patients with limited disease had higher serum Ses2 levels compared to those with extended disease [3.27(1.62, 18.19) vs 0.94(0.81, 2.17) respectively, p=0.024]. However, serum Ses2 levels were not related to disease extend in patients receiving corticosteroids [3.39(1.14, 6.16) vs 0.79(0.53, 5.09) for limited and extended disease respectively p=0.159]. Serum Ses2 levels were higher in patients with no node involvement compared to patients with any node involvement [4.96(1.63, 18.19) vs 1.88(0.88, 3.19) respectively p=0.036]
Conclusion:Serum Ses2 levels are lower in patients with extended sarcoidosis and those with node involvement. Corticosteroids seem to affect serum Ses2 levels. The possible antioxidative role of Ses2 in sarcoidosis has to be further evaluated.
- © 2014 ERS
